Biocept Inc
NASDAQ:BIOC
Intrinsic Value
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. [ Read More ]
The intrinsic value of one
BIOC
stock under the Base Case scenario is
27.6888
USD.
Compared to the current market price of 0.0698 USD,
Biocept Inc
is
Undervalued by 100%.
Biocept Inc's market capitalization is 102.6k USD.
BIOC stock price is 0.0698 USD.
BIOC stock price (0.0698 USD) is 100% less than its Intrinsic Value (27.6888 USD).
BIOC stock price (0.0698 USD) is 100% less than its Relative Value (46.7292 USD). Open Relative Valuation
BIOC.
BIOC's long-term assets (22m USD) exceed its long-term liabilties (22m USD).
BIOC has negative Gross Profit for the last twelve months.
BIOC's short-term assets (9m USD) exceed its short-term liabilties (5m USD).
BIOC's Revenue has dropped by 55% over the past 12 months.
BIOC's ROE (Return on Equity) has significantly decreased in the last 3 years from -28% to -324%, and is approaching profitability.
BIOC's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -38% to -249%, and is approaching profitability.
BIOC has negative Operating Income for the last twelve months.
BIOC has negative Net Income for the last twelve months.
BIOC's ROE (Return on Equity) for the past 12 months is negative and is equal to -324%.
BIOC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -249%.
BIOC has negative Free Cash Flow for the last twelve months.
BIOC's Revenue has been growing by an exceptional 70% per year for the last 3 years.
BIOC has negative three-year average ROE (Return on Equity): -109%. The company is not efficient at transforming stockholders' equity into net income.
BIOC has negative three-year average ROIC (Return on Invested Capital): -135%. The company is not efficient at using invested capital to generate operating income.
BIOC has negative Net Debt. This means that the company has more cash and short-term investments (7m USD) than debt (1m USD).
BIOC's D/E (Debt to Equity) is very high and is equal to 4.7.
BIOC's Altman Z-Score is very low and is equal to -26.64.
BIOC doesn't generate enough operating income (-55m USD) to safely cover interest payments on its debt (195k USD).
Fundamental Analysis
Biocept Inc
Balance Sheet Decomposition
Biocept Inc
| Current Assets | 8.9m |
| Cash & Short-Term Investments | 6.6m |
| Receivables | 800k |
| Other Current Assets | 1.4m |
| Non-Current Assets | 13.2m |
| PP&E | 12.9m |
| Other Non-Current Assets | 386k |
| Current Liabilities | 4.9m |
| Accounts Payable | 1.5m |
| Accrued Liabilities | 2.1m |
| Short-Term Debt | 526k |
| Other Current Liabilities | 815k |
| Non-Current Liabilities | 16.9m |
| Long-Term Debt | 836k |
| Other Non-Current Liabilities | 16.1m |
Earnings Waterfall
Biocept Inc
|
Revenue
|
28.1m
USD
|
|
Cost of Revenue
|
-39.8m
USD
|
|
Gross Profit
|
-11.7m
USD
|
|
Operating Expenses
|
-43.7m
USD
|
|
Operating Income
|
-55.4m
USD
|
|
Other Expenses
|
2.4m
USD
|
|
Net Income
|
-53m
USD
|
Free Cash Flow Analysis
Biocept Inc
What is Free Cash Flow?
BIOC Profitability Score
Profitability Due Diligence
Biocept Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Biocept Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
BIOC Solvency Score
Solvency Due Diligence
Biocept Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Biocept Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOC Price Targets Summary
Biocept Inc
Ownership
BIOC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BIOC Price
Biocept Inc
| Average Annual Return | -15.5% |
| Standard Deviation of Annual Returns | 50.56% |
| Max Drawdown | -100% |
| Market Capitalization | 102.6k USD |
| Shares Outstanding | 1 469 380 |
| Percentage of Shares Shorted | 0.57% |
Company Profile
Biocept Inc
Country
Industry
Market Cap
Dividend Yield
Description
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. The company provides blood-based liquid biopsy technology.
You don't have any saved screeners yet
